Instalab
logoInstalab

4q25 AF Risk Genotype (rs10033464)

Blood Test
Understand one inherited contribution to an irregular heartbeat when it runs in your family.
4.8 (3,721 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
How it works
Order from Instalab
No prescription or your own doctor's order needed
Collect your sample
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a 4q25 AF Risk Genotype (rs10033464) test?

This test is most useful if any of these apply to you.

Curious About Inherited Rhythm Risk
Explore one common genetic risk factor, with the understanding that testing hasn't been shown to improve health outcomes.
Concerned About Early AF in Your Family
A parent or sibling developed AF young, and you want to understand one small part of inherited risk.
Living With Atrial Fibrillation
Understand research on treatment response while keeping treatment choices grounded in your clinical findings.
Reviewing a Consumer DNA Result
Understand what this specific result means and when a conflicting or uncertain genotype needs clinical confirmation.

About 4q25 AF Risk Genotype (rs10033464)

Carrying the risk version of rs10033464 increases your susceptibility to atrial fibrillation. Atrial fibrillation, or AF, is an irregular heart rhythm that starts in the heart's two upper chambers. It can come and go without obvious symptoms, and it raises the risk of stroke.

The association between this variant and AF is well established. Using this single result to choose screening or treatment remains exploratory. A clinical genetic test can identify the variant accurately while still having limited ability to improve medical decisions. Your result describes one inherited contribution to risk; it doesn't diagnose AF or provide a personal lifetime probability.

One Letter Near a Heart-Development Gene

rs10033464 is a position in your DNA on chromosome 4, in a region labeled 4q25. You inherit one copy of this chromosome from each parent. The usual letters reported at this position are G and T, and T is the risk version identified in the published studies.

The position lies outside protein-coding DNA, near PITX2. Experiments in mice show that PITX2 helps establish the heart's left-right pattern and the development of heart muscle around the pulmonary veins. These veins return blood from the lungs to the heart, and electrical activity in the surrounding muscle often starts AF. This provides a biological explanation for interest in the region, but it doesn't establish exactly how rs10033464 affects risk.

A 2026 study examined atrial muscle cells obtained from people without AF and linked rs10033464 to altered calcium handling and abnormal electrical activity. Calcium movement inside these cells helps control their electrical signals and contraction. These human tissue findings support a possible mechanism. In the same study's imaging analysis, larger left atrial size was associated with other 4q25 variants, but not with rs10033464.

Atrial Fibrillation Risk

A large European-ancestry meta-analysis found about 36% higher odds of AF for each T copy. It combined four cohorts with previously published studies. The original discovery study reported a similar association, about 39% higher odds per copy across its European-ancestry samples.

Some smaller studies reported larger associations. Their populations, comparison groups, and genetic models differed, so the figures aren't interchangeable.

Who Was StudiedWhat Was ComparedWhat They Found
713 Hispanic/Latino adultsEach additional T copy, accounting for age, sex, and several clinical risk factorsAbout 2.3 times the odds of AF; this was the only one of eight analyzed variants that remained associated after adjustment
267 adults in an Indian studyT carriers with AF compared with healthy controlsAbout 2.6 times the odds of AF, with substantial uncertainty
410 Polish adults referred for AF ablation and 550 controlsAF cases versus controls matched on age, sex, and hypertension, with additional adjustment for other 4q25 variantsAbout 2.4 times the odds of AF

The Indian study also reported about 4.7 times the odds when it compared people with AF after bypass surgery with healthy controls. That comparison does not show how well the variant distinguishes surgical patients who will develop AF from surgical patients who won't. The estimate was imprecise.

Replication has also varied across populations. The original study did not confirm the rs10033464 association in its Chinese sample, although a neighboring variant did replicate. A small 2026 Polish study found no associations at previously reported AF risk regions after correction for multiple comparisons; with only 56 AF cases, it had limited ability to detect modest effects.

The large European estimate is a useful description of the association in that population. It isn't a personal forecast. A 36% increase in odds does not mean a 36% chance of developing AF, and your absolute risk also depends on age, blood pressure, other heart conditions, and many other genetic variants.

Stroke From a Clot in the Heart

During AF, blood can pool in the upper chambers and form a clot. A clot that travels from the heart to the brain can cause a cardioembolic stroke.

An early study combining several thousand stroke cases with tens of thousands of controls from Iceland and other European populations linked each rs10033464 risk copy to about a quarter higher odds of cardioembolic stroke. A separate multicenter stroke study did not find an association between rs10033464 and ischemic stroke. Its positive finding involved a different 4q25 marker, rs1906591.

A later pooled analysis supported a smaller association between rs10033464 and cardioembolic stroke, about 14% higher odds, without an association with stroke as a whole. These findings connect the variant to the type of stroke associated with AF, but they don't establish a useful standalone assessment of your stroke risk.

Response to Rhythm Drugs and Ablation

Researchers have studied whether rs10033464 helps explain differences in AF treatment response. These studies describe associations; they haven't established that choosing treatment by this genotype improves outcomes.

In two cohorts totaling 676 people with AF, risk-version carriers had more AF recurrence during treatment with rhythm-control drugs. Their odds of recurrence were about 3.3 times higher in the first cohort and 4.3 times higher in the validation cohort over a year. Recurrence was separate from the study's main measure of treatment success, which assessed improvement in symptomatic AF burden. Those figures therefore shouldn't be read as the odds that a drug will provide no benefit.

The same study reported differences in the drug classes used among people who responded. Treatment wasn't randomly assigned by genotype, so those patterns don't establish which medication you should receive.

Catheter ablation creates small areas of damaged heart tissue to block electrical signals that sustain AF. An early study of 195 people associated carrying either of two 4q25 risk variants with recurrence after ablation. A later study of 991 people at three centers found an association for the neighboring rs2200733 variant, but no significant association for rs10033464.

Another study examined 295 people with AF and 70 comparison participants. Within the subgroup of 158 people whose AF came and went, the combination of rs10033464 genotype and blood TIMP-1 was associated with recurrence after ablation. TIMP-1 is a protein involved in tissue remodeling. This exploratory finding hasn't established a routine role for TIMP-1 testing or genotype-based ablation decisions.

Families With Early AF

Some families carry rare variants that strongly affect the heart's electrical channels or muscle. Even among relatives who carry the same disease-associated variant, AF may develop in some and not others.

A study of 70 people from 11 families found that common 4q25 variants, considered together, were associated with whether carriers of rare AF-associated variants had developed AF. This supports a possible modifying role for common variants. It doesn't show that rs10033464 alone identifies the cause of AF in a family or reliably predicts which relative will develop it.

Early AF can sometimes be the first sign of an inherited heart-muscle or electrical disorder. A family history of early AF, heart-muscle disease, or sudden death can therefore matter more to the choice of genetic evaluation than this single common variant.

Limits of a Single Variant

Many people with the T version never develop AF, and many people with AF carry no T copies. The 4q25 region contains several distinct association signals, and AF genetics extends across many other regions of the genome. This result captures a small part of that inherited susceptibility.

Polygenic scores combine many variants. In about 21,000 women, adding a genetic score modestly improved AF prediction, but it did not significantly improve assignment to predefined risk categories. In a study of about 1,700 bypass-surgery patients, adding genetic variants did not significantly improve prediction in the development cohort and produced a small improvement in the validation cohort.

In another study, 904 people with symptoms or clinical risk factors underwent short-term rhythm monitoring. Those in the top fifth of a 12-variant score had about three times the adjusted odds of newly detected AF compared with those in the bottom fifth. This was detection during monitoring, not a threefold rate of developing AF over years.

Newer scores use many more variants and can improve prediction in research cohorts. Their findings don't establish the value of this single-position test. Testing healthy people for rs10033464 has not been shown in a trial to prevent AF or stroke.

When Results Can Be Misleading

  • Coverage: this test identifies the inherited letters at rs10033464. A result without T excludes that risk version at this position; it doesn't exclude other inherited AF risks or a familial heart disorder.
  • Ancestry: the frequency of T and the strength of its association with AF vary across studied populations. Most of the best-established estimates come from European-ancestry cohorts.
  • Consumer reports: raw consumer data and third-party interpretations can contain incorrect calls or assign risk incorrectly. Reports may use opposite DNA-strand conventions, so letters need to be compared using the same orientation and the same rs identifier.
  • Uncertain findings on broader panels: rs10033464 is a known common susceptibility marker. Broader sequencing can also identify variants whose health effects are uncertain. Those uncertain findings should not be treated as confirmed causes of disease.
  • Donor or acquired DNA: after a bone marrow or stem cell transplant from another person, blood can reflect the donor's genotype, and cheek or saliva samples can contain donor DNA too. Tumor-only genetic reports can contain acquired changes and should not automatically be interpreted as inherited results. Tell the collection team about a donor transplant before providing a sample.

A One-Time Result

Your inherited genotype is permanent. Its value, if you choose testing, comes from considering it alongside your family history and clinical findings over time. Follow-up concerns blood pressure and heart rhythm during routine health reviews or when symptoms arise. There is no validated schedule of companion testing based on rs10033464 alone.

Using Your Result

  • An uncertain or conflicting call: clinical confirmation using an independent method, such as sequencing, can resolve a result that could affect care.
  • Palpitations or an irregular pulse: evaluation focuses on documenting the rhythm. An ECG or longer recording may be appropriate regardless of your genotype.
  • Early AF or a concerning family history: a cardiologist or genetic counselor can assess whether a broader inherited-heart-disease evaluation is warranted. Family conversations should include relatives' diagnoses and ages at onset.
  • A stroke without a clear cause: extended rhythm monitoring may be appropriate as part of the stroke workup, whether or not you carry T.
  • Established AF: treatment decisions depend on documented rhythm, symptoms, heart structure, and clinical stroke risk. This genotype currently has no validated role as a standalone drug-selection or ablation-selection rule.

Frequently Asked Questions

Panels containing 4q25 AF Risk Genotype (rs10033464)

4q25 AF Risk Genotype (rs10033464) is included in these pre-built panels.

References

27 studies
  1. Stefan Kääb, Dawood Darbar, Charlotte Van Noord, Josée Dupuis, Arne Pfeufer, Christopher Newton-cheh, Renate B. Schnabel, S. Makino, Moritz F. Sinner, Prince J. Kannankeril, Britt Maria Beckmann, Subbarao Choudry, Brian S. Donahue, Jan Heeringa, Siegfried Perz, Kathryn L. Lunetta, Martin G. Larson, Daniel Levy, Calum a. Macrae, Jeremy N. Ruskin, a. Wacker, Albert Schömig, H.-erich Wichmann, Gerhard Steinbeck, Thomas Meitinger, André G. Uitterlinden, Jacqueline C. M. Witteman, Dan M. Roden, Emelia J. Benjamin, Patrick T. EllinorEuropean Heart Journal2009
  2. Daniel Fannar Gudbjartsson, Davíð O. Arnar, Anna Helgadóttir, Sólveig Grétarsdóttir, Hilma Hólm, ÁSgeir Sigurðsson, Aðalbjörg Jónasdóttir, Adam Baker, Guðmar ÞOrleifsson, Kristleifur Kristjánsson, Arnar Pálsson, Thórarinn Blöndal, Patrick Sulem, Valgerdur M. Backman, Gudmundur a. Hardarson, Ebba Pálsdóttir, Agnar Helgason, Rúna Björg Sigurjonsdottir, Jón ÞóR Sverrisson, Konstantinos Kostulas, Maggie C. Y. Ng, Larry Baum, Wing Yee so, Ka Sing Wong, Juliana C. N. Chan, Karen L. Furie, Steven M. Greenberg, Michelle Sale, Peter J. Kelly, Calum a. Macrae, Eric E. Smith, Jonathan Rosand, Jan Hillert, Ronald C. W. Ma, Patrick T. Ellinor, Guðmundur ÞOrgeirsson, Jeffrey R. Gulcher, Augustine Kong, Unnur ÞOrsteinsdóttir, Kári StefánssonNature2007
  3. Mathilda T. M. Mommersteeg, Nigel a. Brown, Owen W. J. Prall, Corrie De Gier-de Vries, Richard P. Harvey, Antoon F. M. Moorman, Vincent M. ChristoffelsCirculation Research2007
  4. Verónica Jiménez-sábado, Carmen Tarifa, Oliver B. Vad, Sergi Casabella-ramón, Gabriel Manzano-reche, Estefanía Lozano-velasco, Cristina Aceituno, Sheila Caño-carrillo, Jorge N. Domínguez, Christian Paludan-müller, Laura Andreasen, José Montiel, Jose M. Guerra, Diego Franco, Jesper H. Svendsen, Enrique Rodriguez-font, Antonino Ginel, Morten S. Olesen, Leif Hove-madsenCardiovascular Research2026
  5. Brandon Chalazan, Denise Mol, Arvind Sridhar, Zain Alzahrani, Sara D. Darbar, Aylin Ornelas-loredo, Abdullah Farooqui, Maria Argos, Martha L. Daviglus, Sreenivas Konda, Jalees Rehman, Dawood DarbarPLoS ONE2018

4q25 AF Risk Genotype (rs10033464) Testing Option

4q25-AF Risk Genotype

$715

Understand part of your inherited tendency toward an irregular heart rhythm, even before symptoms appear.

Includes 2 biomarkers:
4q25 AF Risk Genotype (rs10033464)4q25 AF Risk Genotype (rs2200733)
FSA/HSA eligible
No Rx needed
HIPAA compliant